Leerink Swann Calls Merck's (MRK) Odanacatib News a 'Positive Upside Surprise'

Article Stock Quotes (1) Comments (0)

Analysts at Leerink Swann this morning called Merck's (NYSE: MRK) early success of odanacatib a "positive upside surprise." Investors seem to be agreeing: Merck shares are up more than 4 percent at last check, marking a more than $5 billion gain in market value.

Leerink sees peak sales for odanacatib at $975 million in 2020, "depending on the final data, see global sales potential of $3B+ if MRK shows a relative reduction in hip fracture risk of 40%+."

The firm maintains an Outperform rating on Merck shares.

Visit our Analyst Ratings page on Merck to see all the market-moving analyst calls.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Merck (MRK) Says Efficacy Not Achieved in Preladenant Phase 3s; Will Discontinue
• Merck Statement on FDA Advisory Committee Meeting for Suvorexant
• Jefferies Lifts Numbers on Diana Shipping (DSX) Post Q1

Create E-mail Alert Related Categories

Analyst Comments

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?